Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi PharmaTech Makes US Acquisition

publication date: Jan 3, 2008

WuXi PharmaTech will pay $151 million to acquire privately held AppTec Laboratory Services of St. Paul, Minn. Like WuXi, AppTec is involved in contract research outsourcing. But, while WuXi concentrates on pre-clinical chemistry services, AppTech provides testing, biologics cGMP manufacturing and contract R&D to the biopharma and medical device sectors.  In 2007, AppTec produced just over $70 million of revenue, representing a compounded growth rate of 46% over the past three years. WuXi predicts its 2007 revenues will approach $135 million. More details... 

Stock Symbols: (NYSE: WX) (NYSE: DNA) 



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital